Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Phio Pharmaceuticals Corp. on August 9, 2022. The filing details the voting results for three key proposals submitted to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting outcomes.
Material Changes and Voting Results
All matters submitted to a vote at the Annual Meeting were approved. The voting breakdown for the 5,700,104 shares present (out of 13,658,722 outstanding) was as follows:
- Proposal 1: Election of Directors - All six nominees were elected. Broker non-votes totaled 4,109,081 shares.
- Proposal 2: Ratification of Auditors - BDO USA, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2022. Votes: 5,443,664 For, 201,639 Against, 54,801 Abstain.
- Proposal 3: Advisory Approval of Executive Compensation - Approved by shareholders. Votes: 1,229,793 For, 236,462 Against, 124,768 Abstain. Broker non-votes totaled 4,109,081 shares.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Confirm the election of the six specific director nominees listed in the filing.
- Verify the ratification of BDO USA, LLP as the auditor for the 2022 fiscal year.
- Note the significant number of broker non-votes (4,109,081) on the director election and executive compensation proposals.
- Review the Definitive Proxy Statement (Schedule 14A) filed on June 30, 2022, for detailed background on the proposals.